MAPK3 and cancer: Classical RAF inhibitors such as vemurafenib and SB590885, or the MEK inhibitor U0126, reduce the entry into S-phase if applied to cancer cells with wild-type RAS and RAF that have pulsatile activation of MEK/ERK1/2.